DropGenie Seed+ Reaches $5M for Patient-Cell Research

Choosing which experiments receive a patient's cells is also choosing which questions get answered. DropGenie, a Montréal and Boston functional-biology company, is building laboratory equipment and services around making that scarce material go further. Its financing now puts a Canadian venture investor closer to the decisions about how the technology reaches researchers.

DropGenie's October 26 announcement describes a $5M Seed+ financing involving BDC Thrive Venture Fund, Skeleton Key, Merck Global Health Innovation Fund, CQDM, Real Ventures and Anges Québec. BetaKit reports that BDC's arrival brings the total equity round to $5M USD. The investment supports commercialization of a platform designed to run gene-editing experiments directly in primary patient cells while consuming less biological material.

The commercial plan reaches beyond putting an instrument on a laboratory bench. DropGenie offers in-lab workflows, studies performed as a service and strategic data partnerships. Those routes give drug developers different ways to obtain experimental results, and give the company several ways to participate in the research that feeds computational discovery.

What the $5M Seed+ announcement changes

The October update follows a Seed+ closing announced on June 22. Skeleton Key led that earlier financing, with Merck Global Health Innovation Fund and CQDM joining as new investors and Real Ventures and Anges Québec continuing their support. That release did not disclose an amount. The $5M now reported is the total equity round after BDC joins; the size of BDC's individual investment remains undisclosed.

The distinction matters to the operating story. A new investor can widen a company's institutional backing without creating a separately disclosed financing of the headline amount. DropGenie's October release says BDC adds a Canadian partner at board level. The company has not disclosed a valuation or a complete lifetime funding total in the announcements reviewed.

June's stated priorities included scaling manufacturing, building commercial operations and accelerating customer adoption. October broadens the explanation of how customers can work with DropGenie. Together, the announcements describe a business preparing to supply both a technology and the experimental work surrounding it, with a broader rollout planned for 2027.

How small experiments preserve more choices

DropGenie's platform uses digital microfluidics to manipulate tiny droplets and electroporation to deliver editing material into cells. Its official product page describes low-volume workflows compatible with laboratory automation. The practical ambition is to make useful experiments possible when the researcher has very little starting material, rather than requiring the sample to meet the appetite of conventional equipment.

A Scientific Reports study published in August 2025 describes 48 independently programmable reaction sites and delivery into as few as 3,000 primary human cells per condition. The researchers applied the platform to an arrayed CRISPR screen in chronically stimulated CD4 T cells. The paper includes DropGenie-affiliated authors and discloses company relationships, so its results should be read within the reported experimental scope.

A July 2026 methods paper indexed by PubMed describes a related workflow using 10,000 cells per condition in primary T-cell experiments, with post-editing viability above 85%. Different conditions explain why a single universal cell-input figure would mislead. The company's broader claim of using up to 100 times fewer cells is a statement about potential reductions across defined workflows, not a promise that every customer's experiment achieves the same result.

For a discovery team, saving material can preserve room for additional conditions, comparisons or follow-up work. That is the commercial importance of miniaturization: an instrument changes the allocation of a sample that cannot be replenished on demand. Buyers still need to assess editing performance, viability and reproducibility in the cells and protocols they actually use.

The founders are selling several ways to do the work

Co-founder and CEO Alison Hirukawa leads DropGenie with co-founders Hugo Sinha and Philippe Vo. The company's team materials identify Hugo Sinha as COO and Philippe Vo as Head of Software. A company-hosted showcase also identifies Alison Hirukawa and Hugo Sinha in those executive roles. Older directory listings carry different titles, making dated company evidence more useful than an inherited founder roster.

The combination of scientific, software and engineering work matters because customers encounter the product through an existing laboratory. Running a protocol internally means incorporating a new tool into that environment. Buying a study as a service moves more experimental execution to DropGenie. A data partnership creates a continuing discussion about which experiments should be repeated and standardized.

These choices distribute work differently. A lab buying access to a platform needs people who can operate and evaluate it. A research leader outsourcing a study needs confidence in the design and resulting evidence. A team building datasets needs consistent definitions and comparable observations. DropGenie's three routes allow those conversations to begin from the customer's research capacity, as well as from the capabilities of the chip.

Where patient-cell research meets AI data demand

DropGenie's financing sits alongside interest in biological data useful for AI-assisted discovery. The company's stated data-partnership strategy aims to produce standardized functional datasets from primary patient cells. Functional experiments change something in a biological system and observe the response, giving researchers a way to test an idea against living material.

The equipment therefore has a place upstream of a computational model. Decisions about cell type, perturbation, measurement and experimental conditions determine what the resulting dataset can explain. Miniaturization can make more of that work feasible with scarce input, while automation can help repeat it. The value to a particular model still depends on the questions the experiments were designed to answer.

For operators considering the platform, that connects procurement to research strategy. The discussion can include who runs the study, how observations are recorded and what evidence supports using the results in another program. Published methods provide a starting point for those discussions; revenue, paid deployment counts and broad commercial performance remain undisclosed in the materials reviewed.

As Alison Hirukawa's team prepares its wider rollout, the same patient sample may sit behind three different buying conversations. One laboratory wants to run the protocol itself, another wants the completed experiment, and a third wants a continuing supply of comparable observations. DropGenie's next commercial chapter will take shape in how those researchers choose to share the work.